Ribonuclear inclusions as biomarker of myotonic dystrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies

European Journal of Histochemistry

Volumn 53, Issue 2, 2009, Pages 107-111

  Cardani, R ^a   Mancinelli, E ^a   Giagnacovo, M ^a   Sansone, V ^a   Meola, Giovanni ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Defrozen muscle biopsy; Fluorescence in situ hybridization; Myotonic dystrophy type 2; Ribonuclear inclusions

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; CNBP PROTEIN, HUMAN; REPETITIVE DNA; RNA BINDING PROTEIN;

ARTICLE; CELL NUCLEUS INCLUSION BODY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; FREEZING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MUSCLE BIOPSY; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 2; PROTEIN DEGRADATION; SKELETAL MUSCLE; STORAGE; TEMPERATURE; BIOPSY; CELL NUCLEUS; CRYOPRESERVATION; FAST MUSCLE FIBER; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; PATHOLOGY; SLOW MUSCLE FIBER;

BIOLOGICAL MARKERS; BIOPSY; CELL NUCLEUS; CRYOPRESERVATION; DNA REPEAT EXPANSION; FREEZING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE, SKELETAL; MYOTONIC DYSTROPHY; RNA, MESSENGER; RNA-BINDING PROTEINS; SPECIMEN HANDLING;

EID: 70349229533     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2009.107     Document Type: Article

References (21)

1. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003; 73:835-848
2. Bassez G, Chapoy E, Bastuji-Garin S, Radvanyi-Hoffman H, Authier FJ, Pellissier JF et al. Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy. J Neuropathol Exp Neurol 2008; 4:319-325
3. Botta A, Caldarola S, Vallo L, Bonifazi E, Fruci D, Gullotta F, et al. Effect of the (CCTG)n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim Biophys Acta 2006;1762:329-334
4. Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 2004; 48:437-442
5. Cardani R, Mancinelli E, Saino G, Bonavina L, Meola G. A putative role of ribonuclear inclusions in the impairment of gallbladder smooth muscle contractility with cholelithiasis in myotonic dystrophy type 1. Neuromuscul Disord 2008; 18:641-645
6. Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002;10:45-53. (Pubitemid 34879148)
7. Dansithong W, Paul S, Comai L, Reddy S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor in DM1. J Biol Chem 2005;280:5773-5780 (Pubitemid 40280057)
8. Day JW, Ranum LPW. RNA pathogeness of the myotonic dystrophies. Neuromuscul Disord 2005; 15:5-16.
9. Dubowitz V. Muscle biopsy: a practical approach. Bailliere Tindall, London 1985;19-40.
10. Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 2004; 303:383-387 (Pubitemid 38095780)
11. Fardaei M, Rogers MT, Thorpe H M, Larkin K, Hamshere MG, Harper PS, et al. Three proteins, MBNL, MBLL and M BXL, co-localize in vivo with nuclear foci of expanded repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 2002; 11:805-814 (Pubitemid 34428648)
12. Liquori CL, Ricker K, Moseley M L, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:816-817
13. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001;10:2165-2170
14. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10:35-44. (Pubitemid 34879147)
15. Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LPW. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZFN9 mRNA processing or protein expression. Hum Mol Genet 2006;15:1808-1815
16. Meola G. Advanced microscopic and histochemical techniques: diagnostic tools in the molecular era of myology. Eur J Histochem 2005;49:93-96
17. Osborne J, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006;15:R162-R169.
18. Sallinen R, Vihola A, Bachinski LL, Huoponen K, Haapasalo H, Hackman P, et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004;14:274-283
19. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley M L, Ranum LPW, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74:1309-1313
20. Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, et al. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. Neuromuscul Disord 2003;13:589-596
21. Vihola A, Bassez G, Meola G, Zhang SI Haapasalo H, Paetau A, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003;60:1854-1857.